We are live on ! Find out more
CCM

Consonance Capital Management Portfolio holdings

AUM $7.28M
1-Year Est. Return 43.59%
This Fund
S&P 500
This Quarter Est. Return
-11.41%
1 Year Est. Return
-43.59%
3 Year Est. Return
+313.86%
5 Year Est. Return
+886.32%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$498M
Cap. Flow
-$243M
Cap. Flow %
-17.89%
Top 10 Hldgs %
76.48%
Holding
31
New
2
Increased
13
Reduced
4
Closed
7

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$81.7M
2
EXEL icon
Exelixis
EXEL
+$49.3M
3
UTHR icon
United Therapeutics
UTHR
+$27.6M
4
MYGN icon
Myriad Genetics
MYGN
+$26M
5
QURE icon
uniQure
QURE
+$23.7M

Top Sells

Rank Stock Value
1
PBYI icon
Puma Biotechnology
PBYI
+$106M
2
NVRO
NEVRO CORP.
NVRO
+$82.4M
3
NUVA
NuVasive, Inc.
NUVA
+$77.3M
4
PACB icon
Pacific Biosciences
PACB
+$70.1M
5
VSTM icon
Verastem
VSTM
+$37.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TBPH icon
26
Theravance Biopharma
TBPH
$874M
– –
-731,909
Closed -$23.9M
VSTM icon
27
Verastem
VSTM
$500M
– –
-429,519
Closed -$37.4M
NVRO
28
DELISTED
NEVRO CORP.
NVRO
– –
-1,446,333
Closed -$82.4M
NUVA
29
DELISTED
NuVasive, Inc.
NUVA
– –
-1,089,523
Closed -$77.3M
RARX
30
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-1,454,761
Closed -$26.3M
1
2

Similar funds

GPC
Garrison Point Capital Walnut Creek, California $6.82M AUM 21.38% 1-Year Est. Return
BPM
Bronson Point Management Fairfield, Connecticut $8.26M AUM 46.43% 1-Year Est. Return
TVPI
True Venture Partners IV Palo Alto, California $8.41M AUM 78.89% 1-Year Est. Return
DCI
Data Collective II Palo Alto, California $8.44M AUM 11.7% 1-Year Est. Return
TPMI
Tilden Park Management I New York $5.38M AUM 28.49% 1-Year Est. Return
TP
Truvvo Partners New York $5.22M AUM 13.74% 1-Year Est. Return
SCG
Siris Capital Group New York $9.42M AUM 42.79% 1-Year Est. Return
CVGI
Craft Ventures GP I San Francisco, California $9.51M AUM 95.77% 1-Year Est. Return

Consonance Capital Management's Q4 2018 Portfolio in Review

As of Q4 2018, Consonance Capital Management held 31 positions worth $1.36B, down 27% from $1.86B the previous quarter. Its ten largest holdings account for 76% of the portfolio.

Consonance Capital Management withdrew a net $243M in Q4 2018, closing 7 positions and reducing 4 holdings. Its most notable exit was Puma Biotechnology, an estimated $106M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Consonance Capital Management opened a new position in Aurinia Pharmaceuticals worth $68K.

  • Consonance Capital Management's largest Q4 2018 buy was Aurinia Pharmaceuticals: 10,000 shares worth $68K.
  • Consonance Capital Management added most to Amarin Corp in Q4 2018, an estimated $81.7M increase.
  • Consonance Capital Management's biggest Q4 2018 reduction was Pacific Biosciences, cutting an estimated $70.1M.
  • Consonance Capital Management fully exited Puma Biotechnology in Q4 2018, selling an estimated $106M.
  • Consonance Capital Management's ten largest holdings make up 76% of its $1.36B portfolio in Q4 2018.
  • Consonance Capital Management opened 2 new positions and closed 7 in Q4 2018.
  • Consonance Capital Management's portfolio value fell 27% quarter-over-quarter to $1.36B.

Based on Consonance Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.